Page last updated: 2024-08-24

topotecan and camptothecin

topotecan has been researched along with camptothecin in 467 studies

Research

Studies (467)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	245 (52.46)	18.2507
2000's	136 (29.12)	29.6817
2010's	75 (16.06)	24.3611
2020's	11 (2.36)	2.80

Authors

Authors	Studies
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL	1
Besterman, JM; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Morton, B; Myers, PL; Peel, M	1
Burke, TG; Mi, Z	1
Besterman, JM; Leitner, P; Manikumar, G; Moore, L; Nicholas, AW; Tele, C; Truesdale, A; Wall, ME; Wani, MC	1
Bigg, DC; Camara, J; Demarquay, D; Harnett, J; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Pla Rodas, F; Pommier, J; Pons, D; Prévost, G; Rolland, A; Schiano-Liberatore, AM; Ulibarri, G	1
Bom, D; Burke, TG; Chavan, AJ; Curran, DP; Fraley, KA; Kruszewski, S; Zimmer, SG	1
Babu, MJ; Damodaran, NK; Deevi, DS; Krishna, CV; Kumar, SA; Sarma, VM; Sastry, TV; Srinivas, AS; Subrahmanyam, D; Venkateswarlu, A	1
Eng, WK; Hecht, SM; Hoch, JM; Johnson, RK; Kingston, DG; Ma, J; Mattern, MR; Newman, DJ; Zhou, BN	1
Carenini, N; Dallavalle, S; De Cesare, M; Delsoldato, T; Ferrari, A; Merlini, L; Penco, S; Perego, P; Pratesi, G; Zunino, F	1
Bingcang, AL; Bom, D; Burke, TG; Chavan, AJ; Curran, DP; Du, W; Fraley, KA; Kohlhagen, G; Kruszewski, S; Latus, LJ; Pommier, Y; Thompson Strode, J; Zimmer, SG	1
Chang, K; Choi, WS; Im, GJ; Kim, DK; Kim, JS; Kim, TK; Kim, YW; Lee, JY; Lee, N; Ryu, DH	1
Beretta, G; Biasotti, B; Carenini, N; Carminati, P; Dallavalle, S; De Cesare, M; Ferrari, A; Gallo, G; Martinelli, R; Marzi, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinti, MO; Zunino, F	1
LaVoie, EJ; Li, TK; Liu, A; Liu, LF; Ruchelman, AL; Singh, SK	1
Bailly, C; Cimetière, B; Hautefaye, P; Hickman, J; Laine, W; Lavielle, G; Léonce, S; Pierré, A	1
Han, R; Pan, XD; Sun, PY	1
LaVoie, EJ; Liu, A; Liu, LF; Ruchelman, AL; Zhou, N; Zhu, S	1
Burgin, AB; Cushman, M; Feese, MD; Pommier, Y; Staker, BL; Stewart, L; Zembower, D	1
Bubley, GJ; Jones, GB; Torregrossa, J	1
Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC	1
Battistuzzi, G; Beretta, GL; Cabri, W; De Cesare, M; Giannini, G; Marastoni, E; Marzi, M; Pisano, C; Vesci, L; Zunino, F	1
Li, Y; Liu, Y; Lu, A; Wang, S; You, Q	1
Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC	2
Cheng, L; Feng, W; LaVoie, EJ; Liu, A; Liu, LF; Satyanarayana, M; Tsai, YC	1
LaVoie, EJ; Liu, AA; Liu, LF; Sharma, L; Tsai, YC	1
Ferguson, DM; Flatten, KS; Gálvez-Peralta, M; Hackbarth, JS; Hiasa, H; Kaufmann, SH; Xing, C	1
Jiang, C; Jin, W; Li, M; Lou, L; Tang, W; You, T; Zheng, C	1
Chen, XG; Chern, JW; Guo, QL; He, XG; Huang, CH; Li, TK; Li, ZY; Wang, XJ; Yang, Q; You, QD	1
Che, X; Cheng, P; Dong, G; Feng, H; Guo, W; Liu, W; Luo, C; Miao, Z; Sheng, C; Wang, J; Wang, W; Xu, Y; Yao, J; You, L; Zhang, J; Zhang, W; Zhou, L; Zhu, L	1
Deng, XQ; Li, L; Li, QY; Lv, H; Su, L; Yao, L; Zhang, Y; Zu, YG	1
Ahluwalia, D; Bhupathi, D; Cai, X; Duan, JX; Hart, CP; Huang, H; Jiao, H; Jung, B; Jung, D; Liu, Q; Matteucci, J; Matteucci, M; Meng, F; Sun, JD	1
Cheng, P; Dong, G; Guo, W; Liu, W; Miao, Z; Sheng, C; Wang, S; Wang, W; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C	1
Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y	1
Dong, G; Guo, Z; Lei, N; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C	1
Huang, Q; Lu, W; Wang, L	1
Dong, G; Fang, K; Guo, Z; Li, J; Liu, Y; Miao, Z; Sheng, C; Wang, S; Wu, S; Wu, Y; Yao, J; Zhang, W; Zhu, L; Zhu, S; Zhuang, C	1
Agama, K; Cushman, M; Kiselev, E; Pommier, Y; Sooryakumar, D	1
Abasolo, I; Bermejo, M; Cabañas, MJ; Corma, A; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Mangas-Sanjuán, V; Rodriguez-Berna, G; Schwartz, S	1
Li, Q; Lian, B; Liu, T; Liu, Y; Wang, W; Yao, L; Zhu, Q	1
Abdelmalak, M; Agama, K; Beck, DE; Cushman, M; Lv, W; Marchand, C; O'Neill, E; Pommier, Y; Reddy, PV; Tender, GS	1
Chen, S; Dong, G; Fang, K; Li, J; Liu, N; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W	1
Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL	1
Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX	1
Goto, M; Hsu, PL; Lee, KH; Liu, YQ; Morris-Natschke, SL; Shang, XF; Song, ZL; Wang, MJ; Yang, CJ; Yang, QR; Zhang, XS	1
Chen, J; Hou, T; Huang, Y; Li, M; Li, X; Liu, F; Ni, J; Pan, P; Sun, H; Tian, S; Wang, X; Yu, H; Zhao, JJ; Zhu, F	1
Bhattacharya, D; Das, BB; Das, SK; Ghosh, A; Kundu, B; Mukherjee, A; Pal, S; Paul Chowdhuri, S; Sarkar, D; Talukdar, A	1
Chen, S; Cheng, J; Dong, G; Fang, K; Huang, Y; Li, Y; Sheng, C; Wang, L; Wu, S	1
Chen, S; Dong, G; Li, X; Liu, D; Ma, Z; Sheng, C; Wu, S	1
Chowdhuri, SP; Das, BB; Das, SK; Kundu, B; Pal, S; Sarkar, D; Talukdar, A	1
Agama, K; An, LK; Hu, DX; Pommier, Y; Tang, WL; Wang, W; Yang, H; Zhang, Y	1
Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H	1
Khil, MS; Kim, JH; Kim, SH; Kolozsvary, A	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1
Brown, T; Burris, HA; Clark, G; Kneuper-Hall, R; O'Rourke, T; Rodriguez, G; Shaffer, D; Von Hoff, DD; Wall, JG; Weiss, G	1
Burris, HA; Hanauske, AR; Hilsenbeck, SG; Johnson, RK; Kuhn, JG; Marshall, MH; Von Hoff, DD	1
Ariyoshi, Y; Sugiura, T	1
Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD	1
Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK	1
Abbruzzese, JL; Anzai, H; Frost, P	1
Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW	1
Betcher, DL; Burnham, N	1
Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL	1
Chen, AY; Liu, LF; Potmesil, M; Wall, ME; Wani, MC; Yu, C	1
Culine, S; Extra, JM; Giacchetti, S; Madelaine, I; Marty, M; Rousseau, F	1
Erlichman, C	1
Kaufmann, SH	1
Slichenmyer, WJ; Von Hoff, DD	1
Beijnen, JH; Goossen, RM; Smith, BR; Underberg, WJ	1
Beijnen, JH; Keijer, WJ; Rodenhuis, S; Smith, BR; ten Bokkel Huinink, WW; Underberg, WJ; van Gijn, R; Vlasveld, LT	1
Bonneterre, J	1
Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ	1
Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL	1
Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Beijnen, JH; Davies, BE; Doyle, E; Rosing, H	1
Ardizzoni, A	1
Ettinger, DS	1
Abe, H; Fujita, H; Ishii, R; Okamoto, M; Takao, A; Takeda, K	1
Abe, H; Arase, H; Fujita, H; Ishii, R; Okamoto, M; Takao, A	1
Burke, TG; Malak, H; Mi, Z	1
Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ	1
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L	1
Jensen, PB; Sehested, M; Sorensen, M	1
Cowan, KH; Horton, JK; Schneider, E; Yang, CJ	1
Arbuck, SG; Cheson, BD; Phillips, PH	1
Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M	1
Barbosa, K; Niedzwiecki, D; Saltz, L; Sirott, M; Tao, Y; Tong, W; Trochanowski, B; Tzy-Jyun, Y; Wright, P; Young, C	1
Sinha, BK	1
Chandan-Langlie, M; Chelstrom, LM; Evans, WE; Jin, J; Reaman, G; Stewart, CF; Uckun, FM; Waddick, KG; White, J	1
Kraut, E; Muller, MT; Staubus, A; Subramanian, D; Young, DC	1
Balis, FM; Blaney, SM; Cole, DE; Godwin, K; Poplack, DG; Sung, C	1
Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR	1
Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F	1
Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR	1
Schellens, JH; Verweij, J	1
Kim, K	1
Beijnen, JH; Davies, BE; de Boer-Dennert, M; Maes, RA; Rosing, H; Schellens, JH; van Warmerdam, LJ; Verweij, J	1
Besterman, JM; Brown, HR; Emerson, DL; Evans, MG; Leitner, PP; Luzzio, MJ; Shaffer, JE; Sternbach, DD; Uehling, D; Vuong, A	1
Ellis, A; Estey, E; Kantarjian, H; Keating, M; O'Brien, S; Zwelling, L	1
Ilson, DH; Law, TM; Motzer, RJ	1
Berger, NA; Chatterjee, S; Cheng, MF	1
Corti, C; Giardini, R; Pratesi, G; Tortoreto, M; Zunino, F	1
Balis, FM; Blaney, SM; Cole, DE; Dedrick, RL; Sung, C	1
Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK	1
Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y	1
Beijnen, JH; Giaccone, G; Peters, GJ; Pinedo, HM; Pizao, PE; Smitskamp-Wilms, E; Van Ark-Otte, J	1
Awada, A; Burris, HA; Cobb, PW; Eckardt, JR; Fields, S; Kuhn, JG; Rinaldi, DA; Smith, L; Von Hoff, DD	1
Burke, TG; Gao, X	1
Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA	1
Ali-Osman, F; Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Griffith, OW; Kaufmann, SH; Moschel, RC; Schold, SC	1
Burris, HA; Fields, SM	1
Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD	1
Frucht, H; Goosenberg, E; Haas, NB; Halbherr, T; LaCreta, FP; O'Dwyer, PJ; Yao, KS	1
Baker, SD; Crom, WR; Heideman, RL; Jones, D; Pratt, CB; Stewart, CF	1
Funk, LR; Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL; Polsky, RM	1
Green, MR	1
Elias, A; Frei, E; Kalish, L; Lynch, TJ; Posner, M; Shulman, LN; Skarin, A; Strauss, G	1
Brennan, JM; Haas, NB; Hudes, GR; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Walczak, J	1
Bowman, L; Furman, W; Heideman, R; Kuttesch, JF; Marina, N; Ochs, J; Pratt, CB; Sandlund, JT; Santana, VM; Stewart, C	1
Chachoua, A; Hochster, H; Liebes, L; Oratz, R; Raphael, B; Sorich, J; Speyer, J; Taubes, B; Vinci, RZ; Wernz, J	1
Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P	1
Beijnen, JH; Maes, RA; Rosing, H; Schellens, JH; van Warmerdam, LJ; Verweij, J	1
Johnson, RK; McCabe, FL	1
Bigner, DD; Friedman, HS; Houghton, PJ; Keir, S; Schold, SC	1
Beijnen, J; de Boer-Dennert, M; Hansen, H; Koier, I; Lund, B; Planting, A; Rosing, H; Verweij, J	1
Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA	1
Creemers, GJ; Lund, B; Verweij, J	1
Donehower, RC; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ	1
Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L	1
Herman, TS; Holden, SA; Khandakar, V; Teicher, BA	1
Bjornsti, MA; Chang, CF; Gordon, J; Kerr, DA; Khalili, K	1
Ardelt, B; Darzynkiewicz, RJ; Darzynkiewicz, Z; Gong, J; Kapuscinski, J; Traganos, F	1
Ara, G; Boscia, RE; Holden, SA; Korbut, T; Teicher, BA	1
Furue, H	1
Balis, FM; Blaney, SM; Cole, DE; Godwin, K; Poplack, DG	1
Arbuck, SG; Cheson, BD	1
Ames, MM; Balis, FM; Blaney, SM; Cole, DE; Craig, C; Hammond, D; Krailo, M; Poplack, DG; Reaman, G; Reid, JM	1
Crumpacker, CS; Dezube, BJ; Li, CJ; Pardee, AB; Zhang, LJ	1
Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A	1
Baker, SD; Crom, WR; Gajjar, A; Heideman, RL; Kuttesch, JF; Stewart, CF	1
Creemers, GJ; Dirix, LY; Gamucci, T; Hudson, I; Schöffski, P; Vallentin, S; Verweij, J; Wanders, J	1
Blackstein, M; Bogues, W; Boos, G; Bramwell, VH; Eisenhauer, EA; Jolivet, J; Knowling, M	1
Donehower, RC; Slichenmyer, WJ	1
Danks, MK; Garrett, KE; Marion, RC; Whipple, DO	1
Buckwalter, CA; Cheng, YC; Kaufmann, SH; Lin, AH; Pommier, YG; Tanizawa, A	1
Antoine, E; Brunel, C; Cathala, G; Derancourt, J; Divita, G; Forné, T; Labourier, E; Riou, JF; Rossi, F; Tazi, J	1
Amsterdam, A; Bajorin, DF; Bosl, GJ; Motzer, RJ; Puc, HS	1
Capranico, G; Caserini, C; Colombo, A; Marchesini, R; Perego, P; Supino, R; Tronconi, M; Zunino, F	1
Baker, SD; Evans, WE; Furman, WL; Pratt, CB; Rivera, GK; Stewart, CF	1
Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B	1
Beijnen, JH; Creemers, GJ; Davies, B; de Boer-Dennert, M; McDonald, M; Rosing, H; Schellens, JH; Verweij, J	1
Champoux, JJ; Ireton, GC; Madden, KR; Parker, LH; Stewart, L	1
Fields, AL; Goldberg, GL; Runowicz, CD	1
Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM	1
Buckwalter, CA; Donehower, RC; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Svingen, PA	1
McNeil, C	1
Bowling, K; Brubaker, A; Chen, TL; Donehower, RC; Ettinger, D; Forastiere, A; Grochow, LB; Ignacio, V; Lubejko, B; O'Reilly, S; Rowinsky, E; Sartorius, S; Slichenmyer, W; Smith, J	1
Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J	1
Bowling, MK; Donehower, RC; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE	1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Law, C	1
Barnett, AA	1
Holzer, G; Karlseder, J; Orel, L; Simon, MM; Sliutz, G; Tempfer, C	1
Dancey, J; Eisenhauer, EA	1
Adamson, PC; Allen, JC; Balis, FM; Berg, SL; Blaney, SM; Heideman, RL; Horowitz, ME; Jakacki, RI; Lange, BJ; Packer, RJ; Phillips, PC; Poplack, DG; Reaman, GH; Sallan, SE	1
Catimel, G; Talon, A	1
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D	1
DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J	1
Fox, SC; Giantonio, BJ; Greenberg, R; Hudes, GR; Kosierowski, R; McAleer, CA; Ozols, RF; Ramsey, HE	1
Loos, WJ; Schellens, JH; Stoter, G; Verweij, J	1
Emami, B; Graham, MV; Harms, W; Matthews, J; Purdy, JA	1
Cairncross, G; Eisenhauer, E; Forsyth, P; Macdonald, D; Sawka, C; Stewart, D; Wainman, N	1
Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Hudson, I; Loos, W; Planting, AS; Schellens, JH; Stoter, G; van Beurden, VM; van der Burg, ME; Verweij, J	1
Alexander, R; Amfoh, K; Engstrom, PF; Fox, S; Green, F; Kosierowski, R; Lusch, C; O'Dwyer, PJ; Raskay, B; Redei, I; Scher, RM	1
Donehower, RC; Grochow, LB; O'Reilly, S; Ord, S; Rowinsky, EK	1
Muller, MT; Subramanian, D	1
Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S	1
Beijnen, JH; Herben, VM; ten Bokkel Huinink, WW	1
Caserini, C; Orlandi, L; Silvestrini, R; Supino, R; Vaglini, M; Zaffaroni, N; Zunino, F	1
Boothman, DA; Lamond, JP; Mehta, MP	1
Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM	1
Crom, WR; Furman, WL; Gajjar, A; Heideman, RL; Houghton, PJ; Meyer, WH; Pratt, CB; Stewart, CF; Zamboni, WC	1
Bell, B; Dryer, ZA; Grier, H; Kurtzberg, J; Pratt, CB; Santana, VM; Stewart, CF; Tubergen, DG; Vietti, TJ; Winick, N; Zamboni, WC	1
Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M	1
Crump, M; Hedley, DW; Nicklee, T	1
Beijnen, JH; Doyle, E; Rosing, H	1
Burke, TG; Gryczynski, I; Lakowicz, JR; Malak, H; Mi, Z	1
Lynch, T	1
Bolis, G; Creemers, GJ; Despax, R; Favalli, G; Gore, M; Guastalla, JP; Hudson, I; Kreinberg, R; Lacave, AJ; Scarfone, G; Ten Bokkel Huinink, WW; Van Belle, S; Verweij, J	1
Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; O'Reilly, S; Rowinsky, EK; Sartorius, S; Slichenmyer, W	1
Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE	1
Mani, S; Ratain, MJ	1
Cooper, JD; Dresler, CM; Emami, B; Graham, MV; Jahanzeb, M; Mortimer, JE	1
Darzynkiewicz, Z; Feldman, E; Halicka, HD; Seiter, K; Traganos, F	1
Buckwalter, CA; Burke, PJ; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Kottke, T; Letendre, L; Rowinsky, EK; Svingen, PA	1
Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC	1
Friedman, HS; Houghton, PJ	1
Willson, JK	1
Broom, C	1
Ganapathi, R; Grabowski, D	1
Bonner, JA; Kozelsky, TF	1
Ahmed, T; Darzynkiewicz, Z; Feldman, EJ; Halicka, HD; Lake, D; Seiter, K; Traganos, F	1
Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Burris, HA; Muggia, FM	1
Gutzler, F	1
Erickson-Miller, CL; May, RD; Murphy, MJ; Osborn, B; Page, JG; Parchment, RE; Tomaszewski, J	1
Armstrong, DK; Cheng, YC; Gore, SD; Kaufmann, SH; Rowinsky, EK; Svingen, PA	1
Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD	1
Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M	1
Tannock, IF; Vukovic, V	1
Berger, NA; Gordon, NH; Mackay, W; Whitacre, CM; Zborowska, E	1
Beijnen, JH; Herben, VM; Hop, E; Kettenes-van den Bosch, JJ; Rosing, H; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM	1
Markman, M	1
Beijnen, JH; Dennis, MJ; Grochow, LB; van Warmerdam, LJ	1
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W	1
Dunton, CJ	1
Janik, JE; Saltz, L	1
Heuser, A; Sauer, R	1
Burke, TG; Warner, DL	1
Crumpacker, CS; Dezube, BJ; Li, CJ; Pardee, AB; Sharma, PL; Zhang, JL	1
Ensley, JF; Lew, D; Rodriguez, GI; Schuller, D; Smith, RE; Taylor, SA	1
Ardizzoni, A; Dombernowsky, P; Gamucci, T; Giaccone, G; Hansen, H; Kaplan, S; Postmus, P; Schaefer, B; Verweij, J; Wanders, J	1
Robert, F; Soong, SJ; Wheeler, RH	1
Berger, NA; Whitacre, CM	1
Ozols, RF	1
Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W	1
Csóka, K; Dhar, S; Fridborg, H; Jonsson, E; Larsson, R; Nygren, P; Sundström, C	1
Bolis, G; Despax, R; Gore, M; Gwyther, S; Hudson, IR; Jiménez-Lacave, A; ten Bokkel Huinink, W; Verweij, J	1
Basi, GS; Earnshaw, WC; Eischen, CM; Kaufmann, SH; Kottke, TJ; Leibson, PJ; Martins, LM; Tung, JS	1
Balcerzak, SP; Gochnour, D; Kraut, EH; Staubus, A; Walker, MJ	1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A	1
Fujimori, A; Hoki, Y; Pommier, Y	1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM	1
de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J	1
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A	1
Furuse, K	1
Sugiyama, T; Ushijima, K; Yakushiji, M	1
Aalders, M; El-Gawly, H; Gabr, A; Kuin, A; Smets, LA	1
Rothenberg, ML	1
Negoro, S	1
Kaye, SB; Vasey, PA	1
Rowinsky, EK; Verweij, J	1
Creemers, GJ	1
Ghaemmaghami, M; Jett, JR	1
Astoul, C; Ollitrault, N; Salvat, D	1
Hecht, SM; Henningfeld, KA; Wang, X	1
Boersma, AW; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J	1
Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM	1
Arbuck, SG; Kieffer, LV; Takimoto, CH	1
Bunn, PA; Kelly, K	1
Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G	1
Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J	1
McCann, J	1
Punt, CJ	1
Brown, R; McDonald, AC	1
Beijnen, JH; Herben, VM; Schellens, JH; Ten Bokkel Huinink, WW	1
de Jonge, MJ; Sparreboom, A; Verweij, J	1
Cnaan, A; Janss, AJ; Levow, C; Phillips, PC; Shpilsky, A; Sutton, L; Zhao, H	1
Arbuck, SG; Takimoto, CH	1
Muggia, FM; O'Leary, J	1
Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL	1
El-Gizawy, SA; Hedaya, MA	1
Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E	1
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC	1
Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P	1
Clements, MK; Cumming, M; Daoud, SS; Jones, CB	1
Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD	1
Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT	1
Chen, AY; Choy, H; Rothenberg, ML	1
Bartussek, C; Naumann, U; Weller, M	1
Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C	1
Blanke, CD; Rothenberg, ML	1
Groshen, S; Keshelava, N; Reynolds, CP	1
Boisdron-Celle, M; Boulanger, N; Gamelin, E	1
Boothman, DA; Huang, TT; Kurama, T; Miyamoto, S; Seufzer, BJ; Shumway, SD; Wuerzberger-Davis, SM	1
Kelly, K	2
Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P	1
Arbuck, SG; Kieffer, LV; Kieffer, ME; Takimoto, CH; Wright, J	1
Allegra, CJ; Grem, JL; Paull, K; Pommier, Y; Voeller, DM	1
Rivory, LP; Robert, J	1
Harada, M; Imai, J; Kawaguchi, T; Kiuchi, S; Okuno, S; Sakamura, Y; Tsuda, N; Tsujihara, K; Yano, S; Yano, T	1
de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J	1
Baccanari, D; Bendele, R; Brown, E; Chiang, S; Desjardins, JP; Dihel, LC; Emerson, DL; Gill, SC; Hamilton, M; LeRay, JD; Luzzio, MJ; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B	1
Sandler, A	1
Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF	1
Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P	1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW	1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J	1
Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY	1
Harada, M; Murata, J; Okuno, S; Sakakibara, H; Sakamura, Y; Suzuki, T	1
Shen, K; Sun, Z; Xu, X	1
Smart, T	2
Learned, J	1
Daoud, SS; Meadows, GG; Redkar, AA	1
Donato, NJ; Ling, YH; Perez-Soler, R	1
Lokich, J	1
Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W	1
Beggiolin, G; Carenini, N; Carminati, P; De Cesare, M; De Isabella, P; Palumbo, M; Perego, P; Pezzoni, G; Pisano, C; Pratesi, G; Scheffer, GL; Tartaglia, L; Zunino, F	1
Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW	1
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S	1
Berg, SL; Blaney, SM; Bomgaars, L	1
Cronk, M; Dunstan, HM; Evans, DR; Goehle, S; Lamb, JR; Ludlow, C; Simon, JA; Szankasi, P	1
Cheng, YC; Lam, W; Park, SY	1
Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G	1
Cunha, KS; Graf, U; Reguly, ML; Rodrigues de Andrade, HH	1
Kato, Y; Saijo, N	1
Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T	1
Houghton, PJ; Santana, VM	1
Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR	1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH	1
Melillo, G; Rapisarda, A; Sausville, EA; Scudiero, DA; Selby, M; Shoemaker, RH; Uranchimeg, B	1
Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J	1
Deslandes, E; Gauduchon, P; Godard, T; Poul, JM; Sichel, F	1
Streltsov, SA	1
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L	1
Carenini, N; Carminati, P; Cucco, C; De Cesare, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Righetti, SC; Vesci, L; Zunino, F	1
Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T	1
Sandler, AB	1
Desai, SD; Gounder, MK; Liu, LF; Rodriguez-Bauman, A; Rubin, EH; Wu, X; Yang, JM; Zhang, H	1
Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA	1
Bucci, F; Carenini, N; Carminati, P; De Cesare, M; Gatti, L; Martinelli, R; Perego, P; Pisano, C; Pratesi, G; Supino, R; Zanier, R; Zuco, V; Zunino, F	1
Bailly, C; Lansiaux, A	1
Nyormoi, O; Satoh, TH; Surmacz, TA; Whitacre, CM	1
Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C	1
Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y	1
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D	1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL	1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M	1
Soepenberg, O; Sparreboom, A; Verweij, J	1
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Pan, XD; Wang, CY	1
Cheung, NK; Kramer, K; Kushner, BH; Modak, S	2
Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K	1
Bottiroli, G; Croce, AC; Favini, E; Supino, R; Zuco, V; Zunino, F	1
Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J	1
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P	1
Hayakawa, Y	1
Holcombe, RF; Kong, KM; Wimmer, D	1
Cho, LC; Choy, H	1
Beijnen, JH; Borst, P; Breedveld, P; Pluim, D; Schellens, JH; Schinkel, AH; Sönmezer, O; Tibben, MM; van Tellingen, O; Zelcer, N	1
Yang, S; Zhang, WN	1
Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K	1
Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C	1
Han, R; Liu, HY; Pan, XD; Sun, PY; Yang, J; Yuan, KH; Zhu, CG	1
Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH	1
Murphy, BA	1
Seiter, K	1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Fujita, F; Fujita, M; Fujiwara, T; Kakushima, M; Kawaguchi, T; Kiuchi, S; Koike, M; Kudoh, S; Okuno, S; Sakamoto, Y; Yano, S; Yano, T	1
Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F	1
Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M	1
Bourget, P; Gravel, E; Mercier, L; Paci, A	1
Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C	1
Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M	1
LaVoie, EJ; Liu, AA; Liu, LF; Ruchelman, AL; Zhou, N; Zhu, S	1
Austin, CA; Curtin, NJ; Smith, LM; Willmore, E	1
Carenini, N; Ciusani, E; Corna, E; Gatti, L; Perego, P; Zunino, F	1
Machida, Y; Onishi, H	1
Antony, S; Burgin, AB; Cushman, M; Ioanoviciu, A; Kohn, KW; Marchand, C; Pommier, Y; Staker, BL; Stewart, L	1
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H	1
Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F	1
Pujol, JL	1
Fournel, P	1
Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS	1
Leu, YL; Prijovich, ZM; Roffler, SR	1
Gupta, AA; Pappo, AS	1
Bellarosa, D; Bigioni, M; Binaschi, M; Crea, A; Goso, C; Maggi, CA; Manzini, S; Palma, C; Parlani, M; Salvatore, C	1
Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A	1
Cai, Y; Chen, Y; Ding, J; Gao, H; Huang, M; Jiang, H; Lin, L; Lu, W; Miao, Z; Shen, H; Zhang, J; Zhang, X; Zhu, H	1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH	1
Caldecott, KW; el-Khamisy, SF; Ju, L; Katyal, S; Li, Y; McKinnon, PJ; Russell, HR	1
Gounder, MK; Kulkarni, D; Nazar, AS; Pungaliya, P; Rubin, EH; Saleem, A; Versace, R	1
Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC	1
Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F	1
Bandrés, E; Enguita, M; García-Foncillas, J; Garrido, MJ; Moreno, D; Trocóniz, IF	1
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB	1
Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT	1
Balsari, A; Carenini, N; De Cesare, M; Perego, P; Petrangolini, G; Pratesi, G; Tortoreto, M; Zunino, F	1
Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML	1
Feun, L; Savaraj, N	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Ferrara, FF; Foderà, R; Guglielmi, MB; Merlini, L; Morini, G; Orlandi, A; Penco, S; Pisano, C; Pratesi, G; Vesci, L; Zuco, V; Zunino, F	1
Chung, SJ; Han, YH; Jin, HE; Kim, DD; Kim, W; Li, H; Shim, CK	1
Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ	1
Srinivas, NR	1
de la Loza, MC; Wellinger, RE	1
Al-Rejaie, SS; Al-Shabanah, OA; Al-Yahya, AA; Aleisa, AM; Ashour, AE; Attia, SM; Bakheet, SA	1
Chen, GQ; Cheng, JK; Han, YH; Liao, SH; Wang, LS; Wang, XL; Xia, L; Zheng, Y	1
Alfonso, J; Balaña-Fouce, R; Ordóñez, C; Ordóñez, D	1
Bucci, F; Cincinelli, R; Croce, AC; Favini, E; Pisano, C; Supino, R; Tortoreto, M; Zuco, V; Zunino, F	1
Bruzzese, F; Budillon, A; Castelli, S; Desideri, A; Di Gennaro, E; Rocco, M	1
Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS	1
Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H	1
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P	1
Antonijevic, MD; Forster, RE; Heaysman, CL; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Small, SA; Tang, Y	1
Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM	1
Dudgeon, DD; Giuliano, KA; Johnston, PA; Lazo, JS; Shinde, SN; Shun, TY; Strock, CJ; Taylor, DL	1
Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z	1
Aucélio, RQ; da Cunha, AL; Marques, FF	1
Gmeiner, WH; Pommier, Y; Reinhold, WC	1
Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M	1
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S	1
Lansiaux, A; Pourquier, P	1
Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H	1
Belinsky, SA; Bernauer, AM; Dacic, S; Dahlberg, SE; Klinge, DM; Liu, Y; Schiller, JH; Siegfried, JM; Tessema, M; Thomas, CL; Yingling, CM	1
Fu, Y; Li, Q; Liu, C; Meng, X; Yao, L; Zhao, X; Zu, B; Zu, Y	1
Miller, G	1
Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y	1
Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M	1
Cantilena, S; D'Acunto, WC; Gnemmi, I; Sala, A; Sottile, F	1
Cheng, P; Dong, G; Guo, W; Lei, N; Liu, W; Miao, Z; Sheng, C; Yao, J; Zhang, W; Zhang, X; Zhu, L; Zhuang, C	1
Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y	1
Hui, C; McVey, M; South, A; Thomas, AM	1
Calabrò, V; Malanga, M; Montariello, D; Quesada, P; Troiano, A	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N	1
Lin, B; Shao, L; Song, Z; Zhang, Y	1
Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O	1
Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J	1
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP	1
Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV	1
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M	1
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T	1
Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P	1
Hamilton, G	1
Aguiar, AC; Alves, BR; Buarque, CD; Cortopassi, WA; Costa, PR; França, TC; Krettli, AU; Penna-Coutinho, J; Pimentel, AS	1
Cheng, D; Chu, C; Li, Q; Li, X; Tong, S; Xu, J; Yan, J	1
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T	1
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM	1
Dong, M; Ju, D; Li, J; Li, Y; Liu, Z; Meng, G; Tan, H; Wang, G; Zhang, Q	1
Arakawa, Y	1
Jeong, M; Kim, JH; Lee, SS; Song, J	1
Gjerset, RA; Zhao, M	1
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR	1
Basler, C; Benner, C; Bouvier, N; Bukreyev, A; Campisi, L; Chen, X; Edwards, M; Fenouil, R; García-Sastre, A; Heinz, S; Ho, JSY; Jin, J; Jordan, S; Lagda, AC; Marazzi, I; Martinez-Gil, L; Merad, M; Metreveli, G; Munoz-Fontela, C; Peralta, Z; Pietzsch, C; Rialdi, A; van Bakel, H; Weirauch, M; Zhao, N	1
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N	1
Krstin, S; Moura, CCM; Peixoto, HS; Tanaka, M; Wang, X; Wink, M	1
Husseini, GA; Ibrahim, M; Sabouni, R	1
Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK	1
Kameoka, M; Nakamichi, K; Nukuzuma, C; Nukuzuma, S; Sugiura, S; Takegami, T; Tasaki, T	1
Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N	1
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K	1
Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I	1
Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X	1
Kim, JC; Kim, JH; Kim, YM; Yoon, YS	1
Qing, L; Qing, W	1
Hu, J; Huang, X; Liu, Y; Nan, X; Wang, H; Yan, L; Zhang, C	1
Jain, A; Jain, SK; Saraf, S; Tiwari, A; Verma, A	1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS	1
Gilkeson, GS; Helke, KL; Oates, JC; Wang, X; Zhang, XK	1
Fu, W; Kai, GY; Li, L; Liu, XF; Liu, YQ; Peng, LZ; Xu, CR; Zhang, M; Zhang, ZJ; Zhu, LZ	1
Bailly, C; Vergoten, G	1
Bai, YP; Li, L; Liu, YQ; Luo, HB; Peng, LZ; Wang, ZP; Xu, CR; Yan, JX; Yang, CJ; Zhang, M; Zhang, ZJ; Zhu, LZ	1

Reviews

83 review(s) available for topotecan and camptothecin

Article	Year
Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. European journal of medicinal chemistry, 2013, Volume: 63 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors	2013
[DNA topoisomerase inhibitor]. Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan	1992
Clinical trials with the topoisomerase I inhibitors. Seminars in oncology, 1992, Volume: 19, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1992
New cytotoxic drugs in clinical development. Nouvelle revue francaise d'hematologie, 1991, Volume: 33, Issue:6 Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Topotecan	1991
Novel chemotherapeutic agents in clinical development. Current opinion in oncology, 1991, Volume: 3, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Mitomycin; Mitomycins; Paclitaxel; Pyrazoles; Quinazolines; Thiophenes; Topotecan	1991
New natural products in cancer chemotherapy. Journal of clinical pharmacology, 1990, Volume: 30, Issue:9 Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan	1990
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]. Bulletin du cancer, 1995, Volume: 82, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting	1995
Camptothecin analogues in the treatment of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Topotecan	1995
New drugs for treating small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
New chemotherapeutic agents in non-small-cell lung cancer. Seminars in oncology, 1993, Volume: 20, Issue:2 Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	1993
Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs, 1995, Volume: 49, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1995
New anticancer agents. Cancer chemotherapy and biological response modifiers, 1994, Volume: 15 Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine	1994
DNA topoisomerase inhibitors. Cancer chemotherapy and biological response modifiers, 1994, Volume: 15 Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1994
New chemotherapeutic agents for non-small cell lung cancer. Chest, 1995, Volume: 107, Issue:6 Suppl Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine	1995
Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematology/oncology clinics of North America, 1994, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1994
New directions for chemotherapy in non-small-cell lung cancer. Chest, 1993, Volume: 103, Issue:4 Suppl Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	1993
Pharmacokinetics and early clinical studies of selected new drugs. Cancer surveys, 1993, Volume: 17 Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan	1993
Topoisomerase I inhibitors: topotecan and irenotecan. Cancer treatment reviews, 1994, Volume: 20, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1994
The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute, 1993, Feb-17, Volume: 85, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; DNA Topoisomerases, Type I; Forecasting; Humans; Irinotecan; Topotecan	1993
[Topoisomerase inhibitors developing in Japan]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan	1993
Recent clinical advances with camptothecin analogues. Cancer treatment and research, 1995, Volume: 78 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan	1995
Promising new therapies in the treatment of advanced ovarian cancer. Cancer, 1995, Nov-15, Volume: 76, Issue:10 Suppl Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan	1995
Current perspectives on camptothecins in cancer treatment. British journal of cancer, 1996, Volume: 74, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
New anticancer agents in clinical development. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan	1995
Clinical pharmacokinetics of topotecan. Clinical pharmacokinetics, 1996, Volume: 31, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Half-Life; Humans; Kidney Diseases; Liver Diseases; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Topotecan	1996
Topoisomerase I interactive drugs in children with cancer. Investigational new drugs, 1996, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Child; DNA Damage; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Topotecan	1996
Promising new agents in oncologic treatment. Current opinion in oncology, 1996, Volume: 8, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan	1996
Factors affecting topotecan sensitivity in human leukemia samples. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Antineoplastic Agents; Camptothecin; Cell Differentiation; Clinical Trials, Phase I as Topic; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Forecasting; Humans; Leukemia; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Topoisomerase-I inhibitors in the management of colon cancer. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1996
Clinical studies of topotecan. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Clinical development of topoisomerase-interactive drugs. Advances in pharmacology (San Diego, Calif.), 1994, Volume: 29B Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1994
An overview of the clinical pharmacology of topotecan. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lactones; Metabolic Clearance Rate; Models, Chemical; Neutropenia; Solubility; Topoisomerase I Inhibitors; Topotecan; Water	1997
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan	1997
New options for the treatment of advanced ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
[Topoisomerase I inhibitor with potential radiosensitizing effect]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan	1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
[Lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine	1997
[Promising new drugs for gynecological cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan	1997
Topoisomerase I inhibitors: review and update. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1997
["State-of-the-art" chemotherapy for small-cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine	1997
Review of phase I clinical studies with topotecan. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Adult; Antineoplastic Agents; Camptothecin; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Topoisomerase I Inhibitors; Topotecan	1997
Topotecan in advanced colorectal cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan	1997
New agents in the treatment of small cell lung cancer. Chest, 1998, Volume: 113, Issue:1 Suppl Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	1998
DNA topoisomerase I inhibitors. Cancer chemotherapy and biological response modifiers, 1997, Volume: 17 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine	1998
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie, 1998, Volume: 80, Issue:3 Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1998
New drugs in the treatment of colorectal carcinoma. Cancer, 1998, Aug-15, Volume: 83, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil	1998
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharmacy world & science : PWS, 1998, Volume: 20, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1998
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer treatment reviews, 1998, Volume: 24, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Paclitaxel; Topoisomerase I Inhibitors; Topotecan	1998
An overview of topoisomerase I-targeting agents. Seminars in hematology, 1998, Volume: 35, Issue:3 Suppl 4 Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1998
Camptothecins: a review of their development and schedules of administration. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan	1998
DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan	1999
Topoisomerase I inhibitors in the treatment of colorectal cancer. Seminars in oncology, 1999, Volume: 26, Issue:6 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	1999
[Pharmacokinetic monitoring]. Bulletin du cancer, 2000, Volume: 87, Issue:1 Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan	2000
New chemotherapy agents for small cell lung cancer. Chest, 2000, Volume: 117, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine	2000
DNA topoisomerase I poisons. Cancer chemotherapy and biological response modifiers, 1999, Volume: 18 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan	1999
[Pharmacology of camptothecin and its derivatives]. Bulletin du cancer, 1995, Volume: 82, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Irinotecan; Mutation; Topotecan	1995
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anti-cancer drugs, 2000, Volume: 11, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2000
Extensive small-cell lung cancer: a treatment overview. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:7 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	2000
Clinical use of topoisomerase I inhibitors in anticancer treatment. Medical and pediatric oncology, 2000, Volume: 35, Issue:4 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2000
Treatment of extensive stage small cell lung cancer. Cancer treatment and research, 2001, Volume: 105 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2001
Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:7 Suppl 8 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2001
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine	2001
The development of camptothecin analogs in childhood cancers. The oncologist, 2001, Volume: 6, Issue:6 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2001
Quantitation of camptothecin and related compounds. Journal of chromatography. B, Biomedical sciences and applications, 2001, Nov-25, Volume: 764, Issue:1-2 Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2001
[Developed new agents for lung cancer]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine	2002
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Current cancer drug targets, 2002, Volume: 2, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2002
Chemotherapy for small cell lung cancer. Seminars in oncology, 2003, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan	2003
Clinical studies of camptothecin and derivatives. The Alkaloids. Chemistry and biology, 2003, Volume: 60 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mutagens; Topotecan	2003
[Current status of camptothecin derivatives as natural antitumor agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2003, Volume: 38, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Structure-Activity Relationship; Topotecan; Tumor Cells, Cultured	2003
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:7 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan	2004
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I]. Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:1 Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2005
Toxicity of the topoisomerase I inhibitors. Expert opinion on drug safety, 2005, Volume: 4, Issue:1 Topics: Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan	2005
Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. Current drug discovery technologies, 2005, Volume: 2, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dextrans; HT29 Cells; Humans; Liposomes; Nanostructures; Neoplasm Transplantation; Polymers; Polymethacrylic Acids; Prodrugs; Topotecan; Treatment Outcome	2005
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2006
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. Future oncology (London, England), 2006, Volume: 2, Issue:5 Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2006
Topoisomerase I inhibitors for the treatment of brain tumors. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2008
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008
[Molecular determinants of response to topoisomerase I inhibitors]. Bulletin du cancer, 2011, Volume: 98, Issue:11 Topics: Camptothecin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2011
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast cancer research and treatment, 2013, Volume: 138, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2013
Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs). Current medicinal chemistry, 2017, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Busulfan; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Carriers; Fluorouracil; Humans; Nanoparticles; Organometallic Compounds; Organoplatinum Compounds; Polymers; Porosity; Succinates; Topotecan	2017

Trials

69 trial(s) available for topotecan and camptothecin

Article	Year
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-cancer drugs, 1992, Volume: 3, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan	1992
Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan	1994
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan	1994
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States	1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1995
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. Journal of the National Cancer Institute, 1993, Sep-15, Volume: 85, Issue:18 Topics: Adult; Aged; Camptothecin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Structure-Activity Relationship; Topotecan	1993
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood, 1995, May-15, Volume: 85, Issue:10 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Camptothecin; Child; Child, Preschool; DNA Damage; Female; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neoplasm Transplantation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	1995
Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer research, 1995, May-15, Volume: 55, Issue:10 Topics: Antineoplastic Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; HeLa Cells; Humans; Lymphoma, Non-Hodgkin; Melanoma; Topotecan	1995
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Infusions, Intravenous; Linear Models; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Remission Induction; Topotecan	1995
Topotecan in chronic lymphocytic leukemia. Cancer, 1995, Mar-01, Volume: 75, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cross-Linking Reagents; DNA Topoisomerases, Type I; DNA-Binding Proteins; DNA, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Topotecan; Treatment Outcome	1995
Phase II trial of topotecan in patients with advanced renal cell carcinoma. Investigational new drugs, 1994, Volume: 12, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan	1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia; Male; Middle Aged; Mouth Mucosa; Quinidine; Remission Induction; Stomatitis; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay	1994
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-cancer drugs, 1994, Volume: 5, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan	1994
Preclinical and phase I trials of topoisomerase I inhibitors. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay	1994
Clinical, pharmacokinetic and biological studies of topotecan. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutrophils; Topotecan	1994
Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9 Topics: Adolescent; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Lactones; Leukocyte Count; Male; Neoplasms; Neutrophils; Platelet Count; Topotecan	1994
Phase II study of topotecan in metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:2 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan; Treatment Outcome	1994
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer research, 1994, Mar-01, Volume: 54, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan	1994
Phase I study of topotecan for pediatric patients with malignant solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Half-Life; Hematopoiesis; Humans; Infusions, Intravenous; Male; Neoplasms; Topotecan; Treatment Outcome	1994
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome	1994
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:8 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Topotecan	1993
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 1993, Mar-01, Volume: 81, Issue:5 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan	1993
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer research, 1993, Mar-01, Volume: 53, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Time Factors; Topotecan	1993
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Topotecan	1995
Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:8 Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Topotecan	1995
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Investigational new drugs, 1995, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Drugs, Investigational; Female; Germinoma; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Topotecan	1995
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Recurrence; Topotecan	1996
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	1996
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. British journal of cancer, 1996, Volume: 73, Issue:10 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Carcinoma, Small Cell; Colonic Neoplasms; Cross-Over Studies; Female; Humans; Hydroxy Acids; Lactones; Male; Metabolic Clearance Rate; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome	1996
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. Journal of the National Cancer Institute, 1996, Jun-19, Volume: 88, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Linear Models; Liver; Liver Diseases; Liver Function Tests; Male; Middle Aged; Topotecan	1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1996
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan	1996
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer, 1996, Aug-01, Volume: 78, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Infant; Infusions, Intravenous; Male; Topotecan	1996
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States	1996
Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Investigational new drugs, 1995, Volume: 13, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostatic Neoplasms; Topotecan; Treatment Outcome	1995
3-D conformal radiotherapy for lung cancer. The Washington University experience. Frontiers of radiation therapy and oncology, 1996, Volume: 29 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Feasibility Studies; Humans; Lung Neoplasms; Lymph Nodes; Missouri; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Thorax; Topotecan	1996
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusion Pumps; Male; Middle Aged; Topotecan	1996
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Investigational new drugs, 1996, Volume: 13, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Topotecan	1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anti-cancer drugs, 1996, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Topotecan	1996
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 1996, Oct-01, Volume: 88, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. Journal of pediatric hematology/oncology, 1996, Volume: 18, Issue:4 Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Hematopoiesis; Humans; Male; Neoplasms; Topotecan	1996
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelium; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	1996
Phase I and pharmacologic study of topotecan in patients with impaired renal function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Reference Values; Topotecan	1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan; Tumor Cells, Cultured	1996
Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. International journal of radiation oncology, biology, physics, 1996, Dec-01, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Thorax; Topotecan	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995]. Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:6 Suppl Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan	1997
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Investigational new drugs, 1996, Volume: 14, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Topotecan	1996
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Dr Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Humans; Lung Neoplasms; Remission Induction; Survival Analysis; Topotecan	1997
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan	1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	1997
Experience with independent radiological review during a topotecan trial in ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Middle Aged; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	1997
Phase II trial of topotecan in malignant melanoma. Cancer investigation, 1997, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Topotecan	1997
Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecologic oncology, 1997, Volume: 66, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome	1997
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan	2000
Phase I clinical trial of weekly combined topotecan and irinotecan. American journal of clinical oncology, 2001, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2001
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan	2004
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. Anti-cancer drugs, 2004, Volume: 15, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting	2004
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome	2006
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan	2008
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2014
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2016
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2018

Other Studies

315 other study(ies) available for topotecan and camptothecin

Article	Year
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Journal of medicinal chemistry, 1991, Volume: 34, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous	1991
Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Journal of medicinal chemistry, 1995, Feb-03, Volume: 38, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Female; Humans; Mice; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water	1995
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Journal of medicinal chemistry, 1994, Jan-07, Volume: 37, Issue:1 Topics: Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Half-Life; Irinotecan; Kinetics; Lactones; Molecular Structure; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Topotecan	1994
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. Journal of medicinal chemistry, 1993, Sep-03, Volume: 36, Issue:18 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred DBA; Molecular Conformation; Molecular Structure; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1993
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. Journal of medicinal chemistry, 1998, Dec-31, Volume: 41, Issue:27 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxepins; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasm Transplantation; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured	1998
Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. Journal of medicinal chemistry, 1999, Aug-12, Volume: 42, Issue:16 Topics: Camptothecin; Chromatography, High Pressure Liquid; Dimyristoylphosphatidylcholine; Drug Stability; Enzyme Inhibitors; Fluorescence Polarization; Humans; Hydrolysis; Phosphatidylglycerols; Spectrometry, Fluorescence; Structure-Activity Relationship; Topoisomerase I Inhibitors	1999
Novel C-ring analogues of 20(S)-camptothecin. Part 3: synthesis and their in vitro cytotoxicity of A-, B- and C-ring analogues. Bioorganic & medicinal chemistry letters, 2000, Feb-21, Volume: 10, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Humans; Structure-Activity Relationship; Tumor Cells, Cultured	2000
Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source. Journal of natural products, 2000, Volume: 63, Issue:9 Topics: Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Spectrum Analysis; Topoisomerase I Inhibitors	2000
Novel 7-substituted camptothecins with potent antitumor activity. Journal of medicinal chemistry, 2000, Oct-19, Volume: 43, Issue:21 Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Structure-Activity Relationship; Tumor Cells, Cultured	2000
The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. Journal of medicinal chemistry, 2000, Oct-19, Volume: 43, Issue:21 Topics: Animals; Antineoplastic Agents; Camptothecin; DNA; Drug Screening Assays, Antitumor; Drug Stability; Electrophoresis, Agar Gel; Humans; Hydrolysis; Kinetics; Mice; Mice, Nude; Organosilicon Compounds; Spectrometry, Fluorescence; Structure-Activity Relationship; Tumor Cells, Cultured	2000
Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues. Journal of medicinal chemistry, 2001, May-10, Volume: 44, Issue:10 Topics: Animals; Antineoplastic Agents; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Humans; Mice; Mice, Nude; Structure-Activity Relationship; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured	2001
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. Journal of medicinal chemistry, 2001, Sep-27, Volume: 44, Issue:20 Topics: Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Imines; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Quantitative Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured	2001
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. Journal of medicinal chemistry, 2003, May-22, Volume: 46, Issue:11 Topics: Amines; Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Naphthyridines; Nitro Compounds; Structure-Activity Relationship; Tumor Cells, Cultured	2003
Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Line, Tumor; DNA; DNA Topoisomerases, Type I; Drug Design; Drug Resistance; Enzyme Inhibitors; Humans; Lactones; Structure-Activity Relationship; Topoisomerase I Inhibitors	2003
Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions. Bioorganic & medicinal chemistry letters, 2003, Nov-03, Volume: 13, Issue:21 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Magnetic Resonance Spectroscopy; Solvents; Structure-Activity Relationship	2003
Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorganic & medicinal chemistry letters, 2004, Nov-15, Volume: 14, Issue:22 Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Naphthyridines; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors	2004
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. Journal of medicinal chemistry, 2005, Apr-07, Volume: 48, Issue:7 Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Carbazoles; Crystallography, X-Ray; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Indenes; Indoles; Intercalating Agents; Isoquinolines; Models, Molecular; Molecular Structure; Mutation; Topoisomerase I Inhibitors	2005
Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha. Bioorganic & medicinal chemistry letters, 2006, Dec-01, Volume: 16, Issue:23 Topics: Camptothecin; Cell Line; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Microwaves; Molecular Structure; Structure-Activity Relationship	2006
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Bioorganic & medicinal chemistry, 2007, Jun-15, Volume: 15, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2007
E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation. Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2008
Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring. Bioorganic & medicinal chemistry letters, 2008, Jul-15, Volume: 18, Issue:14 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Models, Chemical; Oxazines; Topotecan	2008
11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. Bioorganic & medicinal chemistry, 2008, Sep-15, Volume: 16, Issue:18 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors	2008
Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. Bioorganic & medicinal chemistry, 2008, Oct-15, Volume: 16, Issue:20 Topics: Alkylation; Amines; Antineoplastic Agents; Benzene; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Molecular Structure; Naphthyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors	2008
Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones. European journal of medicinal chemistry, 2009, Volume: 44, Issue:4 Topics: Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Inhibitory Concentration 50; Naphthyridines	2009
12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorganic & medicinal chemistry, 2009, Apr-01, Volume: 17, Issue:7 Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Phenanthridines; Topoisomerase I Inhibitors	2009
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Acridines; Aminacrine; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Models, Chemical; Neoplasms; RNA, Small Interfering	2009
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Irinotecan; Models, Chemical; Rhodamines; Structure-Activity Relationship; Topotecan	2009
Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. Journal of medicinal chemistry, 2009, Sep-24, Volume: 52, Issue:18 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Discovery; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Naphthyridines; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Transplantation, Heterologous	2009
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities. Bioorganic & medicinal chemistry, 2010, May-01, Volume: 18, Issue:9 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Esters; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Molecular Structure; Pharmaceutical Solutions; Phosphates; Structure-Activity Relationship	2010
Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38. European journal of medicinal chemistry, 2010, Volume: 45, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Inhibitory Concentration 50; Irinotecan; Nitrogen; Solubility; Water	2010
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. Journal of medicinal chemistry, 2011, Mar-24, Volume: 54, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Brain; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous	2011
Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Antineoplastic Agents; Camptothecin; Cell Proliferation; Crystallography, X-Ray; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2011
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. Journal of medicinal chemistry, 2012, Sep-13, Volume: 55, Issue:17 Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship	2012
Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. European journal of medicinal chemistry, 2012, Volume: 56 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Structure-Activity Relationship	2012
A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Humans; Lactones; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays	2013
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. Journal of medicinal chemistry, 2014, Feb-27, Volume: 57, Issue:4 Topics: Cell Line, Tumor; Humans; Lactams; Magnetic Resonance Spectroscopy; Quinolines; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors	2014
Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. ACS medicinal chemistry letters, 2013, Jul-11, Volume: 4, Issue:7 Topics:	2013
The biological characteristics of a novel camptothecin-artesunate conjugate. Bioorganic & medicinal chemistry letters, 2015, Jan-01, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Camptothecin; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Liver; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays	2015
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore. Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; DNA; Drug Screening Assays, Antitumor; Humans; Hydrogen Bonding; Indenes; Isoquinolines; Molecular Conformation; Protein Binding; Quantum Theory; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Topoisomerase I Inhibitors	2015
Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. Journal of medicinal chemistry, 2015, Aug-27, Volume: 58, Issue:16 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Cycle; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Evodia; Humans; Models, Molecular; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators	2015
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil	2017
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives. Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones	2017
Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives. Bioorganic & medicinal chemistry letters, 2017, 10-15, Volume: 27, Issue:20 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorine; Humans; Structure-Activity Relationship; Topotecan	2017
Structure-Based Drug Design and Identification of H Journal of medicinal chemistry, 2018, 10-11, Volume: 61, Issue:19 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Drug Design; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Sepsis; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Point Mutation; Topoisomerase I Inhibitors	2019
Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer. Journal of medicinal chemistry, 2020, 01-23, Volume: 63, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Drug Design; G2 Phase; HCT116 Cells; Humans; Mice; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators; Xenograft Model Antitumor Assays	2020
Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer. ACS medicinal chemistry letters, 2020, Apr-09, Volume: 11, Issue:4 Topics:	2020
Development of a metabolically stable topoisomerase I poison as anticancer agent. European journal of medicinal chemistry, 2020, Sep-15, Volume: 202 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Humans; Microsomes, Liver; Models, Molecular; Molecular Structure; Recombinant Proteins; Structure-Activity Relationship	2020
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. Journal of medicinal chemistry, 2021, 06-10, Volume: 64, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Binding Sites; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Molecular Dynamics Simulation; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship; Topoisomerase I Inhibitors	2021
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer. European journal of medicinal chemistry, 2022, Jan-15, Volume: 228 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship	2022
Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:3 Topics: Animals; Camptothecin; Combined Modality Therapy; Fibrosarcoma; HeLa Cells; Humans; In Vitro Techniques; Male; Methylcholanthrene; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan	1992
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. Journal of the National Cancer Institute, 1992, Dec-02, Volume: 84, Issue:23 Topics: Antineoplastic Agents; Camptothecin; Chi-Square Distribution; Clone Cells; Humans; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay	1992
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer research, 1992, Apr-15, Volume: 52, Issue:8 Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured	1992
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer research, 1992, Apr-15, Volume: 52, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured	1992
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:3 Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured	1992
Topotecan. Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses, 1992, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Humans; Topotecan	1992
Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer research, 1991, Nov-01, Volume: 51, Issue:21 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Gamma Rays; Leukemia P388; Mice; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1991
Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer research, 1991, Nov-15, Volume: 51, Issue:22 Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Camptothecin; Dihydropyridines; Drug Resistance; Humans; KB Cells; Membrane Glycoproteins; Topotecan	1991
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer research, 1991, Feb-15, Volume: 51, Issue:4 Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured	1991
Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. Journal of pharmaceutical and biomedical analysis, 1990, Volume: 8, Issue:8-12 Topics: Camptothecin; Chromatography, High Pressure Liquid; Cyclodextrins; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Solutions; Temperature; Topotecan	1990
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. Journal of pharmaceutical and biomedical analysis, 1990, Volume: 8, Issue:8-12 Topics: Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Humans; Spectrometry, Fluorescence; Topotecan	1990
High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. Journal of chromatography. B, Biomedical applications, 1995, Jun-09, Volume: 668, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Lactones; Reproducibility of Results; Spectrometry, Fluorescence; Topotecan	1995
[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Half-Life; Infusions, Intravenous; Male; Mice; Mice, Inbred ICR; Rabbits; Sarcoma 180; Topotecan	1995
[Pharmacokinetics of SK & F 104864 in experimental animals. II. Tissue distribution]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Injections, Intravenous; Mice; Mice, Inbred ICR; Sarcoma 180; Tissue Distribution; Topotecan	1995
Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 1995, Oct-24, Volume: 34, Issue:42 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; DNA, Neoplasm; Drug Stability; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescence Polarization; HL-60 Cells; Humans; Irinotecan; Lactones; Molecular Structure; Serum Albumin; Topoisomerase I Inhibitors; Topotecan	1995
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:5 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1995
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. British journal of cancer, 1995, Volume: 72, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carbon Radioisotopes; Carcinoma, Small Cell; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1995
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer research, 1995, Sep-15, Volume: 55, Issue:18 Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1995
Clinical trials referral resource. Trials of topotecan. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Humans; Male; Neoplasms; Topotecan	1995
Intrathecal administration of topotecan in nonhuman primates. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Injections, Spinal; Macaca mulatta; Male; Metabolic Clearance Rate; Time Factors; Topotecan	1995
Topoisomerase I inhibition: a new target or new missiles? Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1995
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests. Computer methods and programs in biomedicine, 1995, Volume: 46, Issue:2 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan	1995
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer research, 1995, Feb-01, Volume: 55, Issue:3 Topics: Animals; Antineoplastic Agents; Body Weight; Camptothecin; Cattle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Thymus Gland; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1995
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncology research, 1994, Volume: 6, Issue:6 Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1994
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. British journal of cancer, 1995, Volume: 71, Issue:3 Topics: Animals; Antineoplastic Agents; Biotransformation; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous	1995
A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer research, 1994, Oct-01, Volume: 54, Issue:19 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Haplorhini; Metabolic Clearance Rate; Models, Biological; Topotecan	1994
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. Journal of the National Cancer Institute, 1994, Oct-19, Volume: 86, Issue:20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine	1994
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochemical pharmacology, 1994, Sep-15, Volume: 48, Issue:6 Topics: Camptothecin; Cell Division; Culture Media; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Gene Expression; Humans; Nuclear Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1994
Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. Journal of pharmaceutical sciences, 1994, Volume: 83, Issue:7 Topics: Antineoplastic Agents; Buffers; Camptothecin; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Humans; Hydrogen-Ion Concentration; Lactones; Liposomes; Phosphatidylcholines; Topotecan	1994
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:3 Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured	1994
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer research, 1994, Jul-01, Volume: 54, Issue:13 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Camptothecin; Carmustine; DNA Polymerase I; DNA Polymerase II; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Male; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Rhabdomyosarcoma; Topotecan; Transferases; Transplantation, Heterologous	1994
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncology research, 1993, Volume: 5, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; DNA Damage; Drug Resistance; Female; Irinotecan; Leukemia P388; Mice; Topotecan	1993
Limited sampling models for topotecan pharmacokinetics. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Humans; Middle Aged; Models, Biological; Models, Statistical; Regression Analysis; Sampling Studies; Topotecan	1994
Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer investigation, 1994, Volume: 12, Issue:3 Topics: Administration, Oral; Animals; Camptothecin; Female; Infusions, Parenteral; Mice; Neoplasms, Experimental; Topotecan	1994
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:2 Topics: Adult; Animals; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Child; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Random Allocation; Time Factors; Topotecan; Transplantation, Heterologous	1994
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:6 Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured	1993
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor. Journal of cancer research and clinical oncology, 1993, Volume: 119, Issue:11 Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cell Hypoxia; Cell Survival; Cisplatin; Combined Modality Therapy; Female; Fibrosarcoma; Hydrogen-Ion Concentration; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1993
Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology, 1993, Volume: 196, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Chloramphenicol O-Acetyltransferase; DNA Replication; DNA Topoisomerases, Type I; Gene Expression Regulation, Viral; Glioma; Humans; JC Virus; Neuroglia; Promoter Regions, Genetic; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Topotecan; Transfection	1993
Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Cancer research, 1993, Oct-01, Volume: 53, Issue:19 Topics: Antineoplastic Agents; Apoptosis; Caffeine; Camptothecin; Cell Cycle; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Topotecan; Tumor Cells, Cultured	1993
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. International journal of cancer, 1993, Jan-02, Volume: 53, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance; Fibrosarcoma; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred C3H; Topotecan; Tumor Cells, Cultured	1993
Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer research, 1993, Feb-15, Volume: 53, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Hydrolysis; Macaca mulatta; Male; Topotecan	1993
Clinical trials referral resource. Clinical trials with topotecan. Oncology (Williston Park, N.Y.), 1993, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Topotecan	1993
Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proceedings of the National Academy of Sciences of the United States of America, 1993, Mar-01, Volume: 90, Issue:5 Topics: Acute Disease; Antiviral Agents; Camptothecin; Cells, Cultured; Chronic Disease; Curcumin; Gene Expression Regulation, Viral; HIV Infections; HIV Long Terminal Repeat; HIV-1; In Vitro Techniques; Naphthoquinones; RNA, Viral; Topotecan; Virus Replication	1993
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor Cancer research, 1993, Jun-15, Volume: 53, Issue:12 Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine	1993
Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3 Topics: Adolescent; Antineoplastic Agents; Bayes Theorem; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous; Male; Statistics, Nonparametric; Topotecan	1996
Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer research, 1996, Apr-01, Volume: 56, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Child; Cytoplasm; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Microscopy, Fluorescence; Topotecan; Tumor Cells, Cultured	1996
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer research, 1996, Apr-01, Volume: 56, Issue:7 Topics: Animals; Camptothecin; Cell Nucleus; Cricetinae; Dichlororibofuranosylbenzimidazole; DNA Topoisomerases, Type I; Humans; Mice; RNA; Topotecan; Tumor Cells, Cultured	1996
Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature, 1996, May-02, Volume: 381, Issue:6577 Topics: Adenosine Triphosphate; Camptothecin; Cell Line; DNA Topoisomerases, Type I; HeLa Cells; Humans; Nuclear Proteins; Phosphorylation; Protein Kinases; Recombinant Proteins; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Topotecan	1996
Interaction of ionizing radiation with topotecan in two human tumor cell lines. International journal of cancer, 1996, May-03, Volume: 66, Issue:3 Topics: Antineoplastic Agents; Blotting, Northern; Brain Neoplasms; Camptothecin; Cell Line; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Gene Expression; Glioblastoma; Humans; Lung Neoplasms; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. The Journal of biological chemistry, 1996, Mar-29, Volume: 271, Issue:13 Topics: Adenosine Triphosphate; Amino Acid Sequence; Base Sequence; Camptothecin; Cations, Divalent; Circular Dichroism; Conserved Sequence; DNA Topoisomerases, Type I; Humans; Kinetics; Magnesium; Molecular Sequence Data; Oligodeoxyribonucleotides; Potassium Chloride; Protein Conformation; Protein Folding; Protein Structure, Secondary; Recombinant Proteins; Topoisomerase I Inhibitors; Topotecan	1996
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. Journal of the National Cancer Institute, 1996, Jun-05, Volume: 88, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Synergism; Humans; Microtubules; Topotecan; Tumor Cells, Cultured	1996
Topotecan: after FDA and ASCO, what's next? Journal of the National Cancer Institute, 1996, Jun-19, Volume: 88, Issue:12 Topics: Antineoplastic Agents; Camptothecin; Female; Genital Neoplasms, Female; Humans; Recurrence; Topotecan; United States; United States Food and Drug Administration	1996
Basic research plays a key role in new patient treatments. Journal of the National Cancer Institute, 1996, Jul-03, Volume: 88, Issue:13 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drugs, Investigational; HIV Protease Inhibitors; Humans; National Institutes of Health (U.S.); Research; Topotecan; United States; United States Food and Drug Administration	1996
FDA approve bark-derived drug. Lancet (London, England), 1996, Jun-08, Volume: 347, Issue:9015 Topics: Antineoplastic Agents; Camptothecin; Drug Approval; Female; Humans; Ovarian Neoplasms; Topotecan; United States; United States Food and Drug Administration	1996
Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. British journal of cancer, 1996, Volume: 74, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Deoxycytidine; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Mice; Quercetin; Topotecan; Transfection; Tumor Cells, Cultured	1996
[Ovarian cancer. The new chemotherapeutic agents]. Soins; la revue de reference infirmiere, 1995, Issue:599 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. Journal of chromatography. B, Biomedical applications, 1996, Apr-12, Volume: 678, Issue:2 Topics: Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hydroxy Acids; Kinetics; Regression Analysis; Sensitivity and Specificity; Topoisomerase I Inhibitors; Topotecan	1996
Trial of topotecan as first-line treatment for ovarian cancer announced. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan	1996
Topotecan demonstrates significant activity in small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Remission Induction; Topotecan	1996
Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncology research, 1995, Volume: 7, Issue:9 Topics: Antineoplastic Agents; Biological Assay; Camptothecin; Chromatography, High Pressure Liquid; DNA; DNA Adducts; DNA Helicases; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; HeLa Cells; Humans; Liposomes; Topoisomerase I Inhibitors; Topotecan	1995
Topotecan's potency linked to presence of albumin. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:2 Topics: Albumins; Antineoplastic Agents; Camptothecin; Humans; Topotecan	1996
Topotecan approved for cancer chemotherapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Aug-01, Volume: 53, Issue:15 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Topotecan	1996
Modulation of melphalan cytotoxic activity in human melanoma cell lines. Anti-cancer drugs, 1996, Volume: 7, Issue:5 Topics: Antineoplastic Agents, Alkylating; Blotting, Northern; Camptothecin; Drug Interactions; Enzyme Inhibitors; Ethacrynic Acid; Humans; Melanoma; Melphalan; Temperature; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of neuro-oncology, 1996, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Central Nervous System Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan	1996
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. International journal of radiation oncology, biology, physics, 1996, Sep-01, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Neoplasms; Radiation Dosage; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Topotecan hydrochloride for metastatic ovarian cancer. The Medical letter on drugs and therapeutics, 1996, Oct-25, Volume: 38, Issue:986 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry, 1996, Nov-01, Volume: 25, Issue:3 Topics: Animals; Antibody Specificity; Camptothecin; Cell Cycle; DNA Topoisomerases, Type II; Enzyme Inhibitors; Fluorescence; Humans; Image Cytometry; Leukemia, Myeloid; Rabbits; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Topotecan demonstrates significant activity in recurrent small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	1996
The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. Journal of pharmaceutical and biomedical analysis, 1996, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Humans; Rats; Temperature; Topotecan	1996
Fluorescence detection of the anticancer drug topotecan in plasma and whole blood by two-photon excitation. Analytical biochemistry, 1996, Nov-15, Volume: 242, Issue:2 Topics: Antineoplastic Agents; Blood Chemical Analysis; Camptothecin; Chemistry Techniques, Analytical; Humans; Infrared Rays; Lasers; Male; Photons; Plasma; Skin; Spectrometry, Fluorescence; Topotecan	1996
Topotecan today. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Topotecan	1996
Hycamtin achieves promising results in study of patients with leukemia. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan	1996
Induction of apoptosis by camptothecin and topotecan. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow; Camptothecin; Cell Cycle; Cytarabine; DNA Damage; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Topotecan	1996
Schedule-dependent efficacy of camptothecins in models of human cancer. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Treatment of central nervous system xenografts with camptothecins. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous	1996
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan	1996
The significance of the sequence of administration of topotecan and etoposide. Cancer chemotherapy and pharmacology, 1996, Volume: 39, Issue:1-2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Cells, Cultured; Cricetinae; Drug Synergism; Enzyme Inhibitors; Etoposide; Fibroblasts; Lung; Topoisomerase I Inhibitors; Topotecan	1996
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Camptothecin; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan	1997
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; DNA Fragmentation; DNA, Neoplasm; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan	1997
[New drugs. Topoisomerase inhibitors]. Zentralblatt fur Gynakologie, 1996, Volume: 118, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1996
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Cells, Cultured; Colony-Forming Units Assay; Dogs; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-3; Mice; Recombinant Proteins; Topoisomerase II Inhibitors; Topotecan	1997
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood, 1997, Mar-15, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Camptothecin; DNA Adducts; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Enzyme Stability; Humans; Leukemia; Prospective Studies; Topotecan	1997
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. British journal of cancer, 1997, Volume: 75, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured	1997
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. British journal of cancer, 1997, Volume: 75, Issue:8 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms	1997
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer research, 1997, Apr-15, Volume: 57, Issue:8 Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Humans; Isoenzymes; Mice; Mice, Nude; Neoplasm Proteins; Topoisomerase II Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation	1997
Second-line therapy. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 1997, Feb-12, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Failure	1997
Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:6 Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Spectrometry, Fluorescence; Topotecan	1997
Topotecan: an important new drug in the management of ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. Journal of chromatography. B, Biomedical sciences and applications, 1997, Mar-28, Volume: 691, Issue:1 Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan	1997
Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:5 Topics: Camptothecin; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Topoisomerase I Inhibitors; Topotecan; Tumor Necrosis Factor-alpha; Virus Replication	1997
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase. Cancer research, 1997, Jun-01, Volume: 57, Issue:11 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Adhesion; Chromatin; Fibronectins; HeLa Cells; Humans; Methacrylates; Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Topotecan; Tumor Cells, Cultured	1997
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	1997
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. British journal of cancer, 1997, Volume: 76, Issue:2 Topics: Camptothecin; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunohistochemistry; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1997
Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 1997, Aug-01, Volume: 90, Issue:3 Topics: Affinity Labels; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Camptothecin; Caspase 3; Caspase 7; Caspases; Cisplatin; Cysteine Endopeptidases; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Lamin Type B; Lamins; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Methotrexate; Neoplasm Proteins; Nuclear Proteins; Oligopeptides; Poly(ADP-ribose) Polymerases; Staurosporine; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured	1997
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water	1997
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:5 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; KB Cells; Time Factors; Topotecan; Up-Regulation	1997
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1997
Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer research, 1997, Nov-01, Volume: 57, Issue:21 Topics: Animals; Antineoplastic Agents; Camptothecin; DNA, Neoplasm; Hydrogen-Ion Concentration; Leukemia L1210; Mice; Mice, Inbred C3H; Topotecan	1997
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? British journal of cancer, 1997, Volume: 76, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1997
[Derivatives of camptothecin. A new class of antineoplastic agents]. Soins; la revue de reference infirmiere, 1997, Issue:621 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan	1997
DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors. Biochemistry, 1998, Feb-24, Volume: 37, Issue:8 Topics: Animals; Base Sequence; Benzophenanthridines; Berberine Alkaloids; Binding Sites; Calcium; Camptothecin; Cations, Divalent; Cattle; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; In Vitro Techniques; Kinetics; Magnesium; Nucleic Acid Conformation; Oligodeoxyribonucleotides; Phenanthridines; Substrate Specificity; Topoisomerase I Inhibitors; Topotecan	1998
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Irinotecan; Topotecan; Tumor Cells, Cultured	1998
DNA-topoisomerase I, a new target for the treatment of neuroblastoma. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:12 Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous	1997
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. British journal of cancer, 1998, Volume: 77, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan	1998
Colon cancer: new drug options improve on 5-FU. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1998
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British journal of cancer, 1998, Volume: 78, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	1998
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anti-cancer drugs, 1998, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1998
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine	1999
Comparative brain tissue distribution of camptothecin and topotecan in the rat. Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:5 Topics: Animals; Antineoplastic Agents; Brain; Camptothecin; Extracellular Space; Injections, Intravenous; Male; Microdialysis; Rats; Rats, Wistar; Tissue Distribution; Topotecan	1999
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1999
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer research, 1999, Sep-15, Volume: 59, Issue:18 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. International journal of oncology, 1999, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1999
Antiangiogenic potential of camptothecin and topotecan. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Camptothecin; Cell Cycle; Cell Division; Cells, Cultured; Endothelium, Vascular; Humans; Liposomes; Male; Neovascularization, Physiologic; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Topotecan; Umbilical Veins	1999
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells. Anti-cancer drugs, 1999, Volume: 10, Issue:7 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured	1999
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer research, 1999, Oct-01, Volume: 59, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1999
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Experimental cell research, 1999, Dec-15, Volume: 253, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Cell Death; Cell Division; Cisplatin; Clone Cells; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, Dominant; Glioma; Humans; In Vitro Techniques; Paclitaxel; Point Mutation; Radiotherapy; Teniposide; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vincristine	1999
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer research, 1999, Dec-01, Volume: 59, Issue:23 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured	1999
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured	2000
NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. The Journal of biological chemistry, 2000, Mar-31, Volume: 275, Issue:13 Topics: Apoptosis; Base Sequence; Camptothecin; Cell Nucleus; Cysteine Endopeptidases; Cytoplasm; DNA Damage; DNA Primers; DNA Replication; DNA-Binding Proteins; HeLa Cells; Humans; I-kappa B Proteins; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; S Phase; Signal Transduction; Topotecan; Ubiquitins	2000
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured	2000
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Phosphorylation; Thymidine Kinase; Thymidylate Synthase; Time Factors; Topotecan; Tumor Cells, Cultured; Zidovudine	2000
Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Animals; Breast Neoplasms; Camptothecin; Cell Cycle; Chromatography, Gel; Chromatography, High Pressure Liquid; Dextrans; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Rats; Rats, Wistar; Time Factors; Tissue Distribution; Topotecan; Tumor Cells, Cultured	2000
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Carbon Radioisotopes; Drug Carriers; Female; Humans; KB Cells; Liposomes; Mice; Mice, Nude; Sarcoma; Tissue Distribution; Topotecan; Xenograft Model Antitumor Assays	2000
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:16 Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured	2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2000
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer research, 2001, Jan-15, Volume: 61, Issue:2 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2001
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. Journal of controlled release : official journal of the Controlled Release Society, 2001, Mar-12, Volume: 71, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carbohydrate Sequence; Cell Line; Chromatography; Dextrans; Female; Half-Life; Macrophages; Molecular Sequence Data; Neoplasms, Experimental; Prodrugs; Rats; Rats, Wistar; Tissue Distribution; Topotecan	2001
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
PML and a tale of two drug companies. Notes from the underground (New York, N.Y.), 1995,Winter, Issue:no 29 Topics: AIDS-Related Opportunistic Infections; Albendazole; Blood-Brain Barrier; Camptothecin; Drug Industry; Humans; Irinotecan; JC Virus; Leukoencephalopathy, Progressive Multifocal; Microsporidiosis; Polymerase Chain Reaction; Topotecan	1995
Topotecan now available for HIV, PML research. AIDS treatment news, 1995, Apr-07, Issue:no 220 Topics: Antineoplastic Agents; Camptothecin; HIV Infections; Humans; Leukoencephalopathy, Progressive Multifocal; Topotecan	1995
Topotecan research moves forward at last. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:4 Topics: Antineoplastic Agents; Antiviral Agents; Camptothecin; Clinical Trials as Topic; HIV Long Terminal Repeat; HIV-1; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma; Mutation; Sarcoma, Kaposi; Topoisomerase I Inhibitors; Topotecan; Virus Replication	1995
Making inroads on PML. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Camptothecin; HIV Protease Inhibitors; Humans; Irinotecan; Leukoencephalopathy, Progressive Multifocal; Topotecan	1996
Topotecan and PML: the limits of pharmaceutical industry research. Notes from the underground (New York, N.Y.), 1996, Issue:No 33 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Consumer Advocacy; Drug Approval; Drug Evaluation, Preclinical; Drug Industry; Health Services Accessibility; HIV Infections; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ovarian Neoplasms; Topotecan	1996
PML update. Critical Path AIDS project, 1997,Summer, Issue:No 32 Topics: Acquired Immunodeficiency Syndrome; Camptothecin; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Topotecan	1997
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. International journal of oncology, 2001, Volume: 19, Issue:1 Topics: Alkaloids; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Bromodeoxyuridine; Camptothecin; Cell Division; Colony-Forming Units Assay; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Staurosporine; Topoisomerase I Inhibitors; Topotecan	2001
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:6 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2001
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer research, 2001, Aug-15, Volume: 61, Issue:16 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; DNA Damage; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; HT29 Cells; Humans; Mice; Mice, Nude; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Topotecan; Xenograft Model Antitumor Assays	2001
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer research, 2001, Sep-15, Volume: 61, Issue:18 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus	2001
Cell-based assays for identification of novel double-strand break-inducing agents. Journal of the National Cancer Institute, 2002, Jan-16, Volume: 94, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Idarubicin; Mutation; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2002
X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer research, 2002, Jan-15, Volume: 62, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; KB Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topotecan; Transfection; X-ray Repair Cross Complementing Protein 1	2002
Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination. Mutagenesis, 2002, Volume: 17, Issue:2 Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Damage; Drosophila melanogaster; Enzyme Inhibitors; Female; Irinotecan; Male; Mutagenicity Tests; Mutation; Recombination, Genetic; Topoisomerase I Inhibitors; Topotecan; Wings, Animal	2002
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection	2002
Clinical trials using irinotecan. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2002
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. British journal of cancer, 2002, May-20, Volume: 86, Issue:10 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays	2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. International journal of cancer, 2002, Jul-01, Volume: 100, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; DNA, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Gene Expression; Glioma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Lymphokines; Nuclear Proteins; Promoter Regions, Genetic; Response Elements; RNA, Messenger; Topotecan; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutation research, 2002, Sep-26, Volume: 520, Issue:1-2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; CHO Cells; Comet Assay; Cricetinae; DNA Damage; DNA Fragmentation; Ellipticines; Enzyme Inhibitors; Etoposide; Formazans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2002
Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I. Journal of biomolecular structure & dynamics, 2002, Volume: 20, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dimerization; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Molecular; Molecular Structure; Nucleic Acid Heteroduplexes; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2002
Unexpected pleural effusions in 3 pediatric patients treated with STI-571. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:8 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan	2002
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2002
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Molecular cancer therapeutics, 2002, Volume: 1, Issue:8 Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured	2002
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Molecular and cellular biology, 2003, Volume: 23, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cricetinae; DNA; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Haplorhini; Humans; Lung; Lymphocytes; Macromolecular Substances; Mice; Mice, Nude; Neoplasms; Nucleic Acid Synthesis Inhibitors; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Subunits; RNA Polymerase II; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Xenograft Model Antitumor Assays	2003
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. International journal of oncology, 2003, Volume: 22, Issue:5 Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53	2003
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochemical pharmacology, 2003, Apr-15, Volume: 65, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA Damage; DNA, Neoplasm; Humans; Male; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured	2003
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins. Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al, 2003, Volume: 27, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase 9; Caspases; Cell Adhesion; Enzyme Activation; Enzyme Precursors; Female; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotides, Antisense; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Sensitivity and Specificity; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1	2003
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines. European journal of pharmacology, 2003, Jul-25, Volume: 473, Issue:2-3 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan	2003
Expression and functional analyses of breast cancer resistance protein in lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan	2003
Apoptotic pathways of epothilone BMS 310705. Gynecologic oncology, 2003, Volume: 91, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured	2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured	2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. International journal of cancer, 2004, Jan-01, Volume: 108, Issue:1 Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 1 Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan	2004
Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer research, 2004, Feb-15, Volume: 64, Issue:4 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan	2004
Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochemical pharmacology, 2004, Mar-15, Volume: 67, Issue:6 Topics: Antineoplastic Agents; Camptothecin; DNA Damage; HT29 Cells; Humans; Spectrometry, Fluorescence; Subcellular Fractions; Topotecan; Tumor Cells, Cultured	2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer research, 2004, Apr-01, Volume: 64, Issue:7 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan	2004
[Structure-activity relationship analysis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine	2004
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer research, 2004, Aug-15, Volume: 64, Issue:16 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Baculoviridae; Benzimidazoles; Biological Transport; Camptothecin; Cell Line; DNA, Complementary; Dogs; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Membrane Transport Proteins; Methotrexate; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Omeprazole; Pantoprazole; Spodoptera; Sulfoxides; Topotecan; Transfection	2004
Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Molecular cancer therapeutics, 2004, Volume: 3, Issue:9 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan	2004
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. The Journal of biological chemistry, 2004, Dec-24, Volume: 279, Issue:52 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
[Synthesis and antitumor activity of 20-O-linked camptothecin ester derivatives]. Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:8 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Esters; Female; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred ICR; Molecular Structure; Neoplasm Transplantation; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2004
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer research, 2004, Dec-15, Volume: 64, Issue:24 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha	2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer research, 2005, Feb-15, Volume: 65, Issue:4 Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4 Topics: Animals; Antineoplastic Agents; Area Under Curve; Body Weight; Camptothecin; Cell Line, Tumor; Dextrans; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Time Factors; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays	2005
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2005
Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Antineoplastic Agents; Calibration; Camptothecin; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Densitometry; Drug Industry; Drug Stability; Irinotecan; Models, Chemical; Pharmaceutical Preparations; Quality Control; Reproducibility of Results; Spectrometry, Fluorescence; Technology, Pharmaceutical; Topotecan	2005
Cancer cell adaptation to chemotherapy. BMC cancer, 2005, Jul-18, Volume: 5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation	2005
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochemical pharmacology, 2005, Oct-15, Volume: 70, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan	2005
Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. Bioorganic & medicinal chemistry, 2005, Dec-15, Volume: 13, Issue:24 Topics: Amides; Camptothecin; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Esters; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Topoisomerase I Inhibitors; Topotecan	2005
The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Animals; Antineoplastic Agents, Phytogenic; Azulenes; Benzodiazepines; Camptothecin; CHO Cells; Cricetinae; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Female; Fibroblasts; Humans; K562 Cells; Mice; Mice, Knockout; Poly(ADP-ribose) Polymerase Inhibitors; Topoisomerase I Inhibitors; Topotecan; Tumor Stem Cell Assay	2005
Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Silencing; Genetic Vectors; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transfection; Tumor Necrosis Factor-alpha; Up-Regulation	2006
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Molecular cancer therapeutics, 2006, Volume: 5, Issue:2 Topics: Camptothecin; Crystallography; DNA; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Hydrogen Bonding; Indenes; Isoquinolines; Molecular Structure; Topoisomerase I Inhibitors; Topotecan	2006
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5 Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan	2006
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:3 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases	2006
[Is small cell lung cancer an orphan disease?]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine	2006
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan	2006
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA Fragmentation; Dose-Response Relationship, Drug; Glucuronidase; Glucuronides; Humans; Hybridomas; Hydrogen-Ion Concentration; Hydrolysis; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Lactones; Molecular Structure; Prodrugs; Serum Albumin; Thymidine; Time Factors; Topotecan; Tritium	2007
Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate. Anti-cancer drugs, 2006, Volume: 17, Issue:10 Topics: Animals; Camptothecin; Cathepsin B; Cells, Cultured; Dextrans; Humans; Immunity, Cellular; Macrophages; Mice; Models, Biological; Phagocytosis; Polysaccharides; Prodrugs; Topotecan	2006
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatric blood & cancer, 2007, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine	2007
Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4 Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; HL-60 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Topotecan	2007
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan	2008
TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. The EMBO journal, 2007, Nov-14, Volume: 26, Issue:22 Topics: Animals; Antineoplastic Agents; Astrocytes; Bone Marrow Cells; Camptothecin; Cell Differentiation; Cells, Cultured; Cerebellum; Cholesterol; DNA Breaks, Single-Stranded; DNA Repair; DNA Topoisomerases, Type I; Female; Gamma Rays; Hydrogen Peroxide; Intestines; Male; Mice; Mice, Knockout; Neurons; Phosphoric Diester Hydrolases; Serum Albumin; Spleen; Thymus Gland; Topotecan	2007
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dogs; Drug Resistance, Neoplasm; Gene Expression; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Topotecan; Transfection	2008
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan	2007
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? The EMBO journal, 2007, Nov-14, Volume: 26, Issue:22 Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan	2007
Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:1 Topics: Algorithms; Animals; Antineoplastic Agents; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Inhibitory Concentration 50; Rats; Signal Transduction; Time Factors; Topotecan	2008
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Current medical research and opinion, 2008, Volume: 24, Issue:4 Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine	2008
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer biology & therapy, 2008, Volume: 7, Issue:4 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Xenograft Model Antitumor Assays	2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leukemia & lymphoma, 2008, Volume: 49, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan	2008
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Molecular cancer therapeutics, 2008, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Female; Humans; Mice; Mice, Nude; Microbial Viability; Mutant Proteins; Saccharomyces cerevisiae; Topotecan; Xenograft Model Antitumor Assays	2008
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharmaceutical research, 2008, Volume: 25, Issue:11 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Camptothecin; Dogs; Humans; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Rats; Rats, Sprague-Dawley; Topotecan	2008
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Molecular cancer therapeutics, 2008, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays	2008
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? Biomedical chromatography : BMC, 2009, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mice; Myocardium; Tandem Mass Spectrometry; Topotecan	2009
A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan. Nucleic acids research, 2009, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Camptothecin; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type I; DNA, Mitochondrial; Mitochondria; Saccharomyces cerevisiae; Topotecan	2009
Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan. Environmental and molecular mutagenesis, 2009, Volume: 50, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cytogenetics; DNA Probes; DNA, Satellite; In Situ Hybridization, Fluorescence; Injections, Intraperitoneal; Irinotecan; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Topotecan	2009
NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics, 2009, Volume: 9, Issue:8 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Down-Regulation; Doxorubicin; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Protein Kinase C-delta; RNA, Small Interfering; Topotecan; Transcription, Genetic; U937 Cells	2009
Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum. Journal of biomedicine & biotechnology, 2009, Volume: 2009 Topics: Amino Acid Sequence; Animals; Camptothecin; Cryptosporidium parvum; DNA Topoisomerases, Type I; Gene Expression Regulation, Enzymologic; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutant Proteins; Saccharomyces cerevisiae; Sequence Alignment; Topotecan	2009
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochemical pharmacology, 2010, Feb-15, Volume: 79, Issue:4 Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Topotecan; Xenograft Model Antitumor Assays	2010
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Molecular cancer therapeutics, 2009, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; Reactive Oxygen Species; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Vorinostat	2009
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan	2010
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays	2010
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays	2010
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. Journal of materials science. Materials in medicine, 2010, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Pancreatic Neoplasms; Topotecan	2010
[Hematological toxicity of some combined chemotherapy schemes involving aranoza]. Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan	2010
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. Assay and drug development technologies, 2010, Volume: 8, Issue:4 Topics: Antineoplastic Agents; Biosensing Techniques; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 2; Ellipticines; Genes, p53; High-Throughput Screening Assays; Humans; Imidazoles; Mitoxantrone; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Small Molecule Libraries; Spectrometry, Fluorescence; Topotecan; Tumor Suppressor Protein p53	2010
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. The Journal of surgical research, 2011, Volume: 171, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays	2011
Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin. Talanta, 2010, Nov-15, Volume: 83, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorescence; Irinotecan; Lasers; Pharmaceutical Preparations; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Topotecan	2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatric blood & cancer, 2011, Volume: 56, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome	2011
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Molecular cancer therapeutics, 2010, Volume: 9, Issue:12 Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States	2010
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. Brain tumor pathology, 2011, Volume: 28, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine	2011
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. European journal of pharmacology, 2011, Nov-16, Volume: 670, Issue:1 Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan	2011
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2012, Volume: 81, Issue:1 Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan	2012
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene, 2012, Sep-13, Volume: 31, Issue:37 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cytokines; DNA Methylation; DNA Topoisomerases, Type I; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sulfatases; Sulfotransferases; Topoisomerase I Inhibitors; Topotecan; Ubiquitins	2012
In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity. International journal of pharmaceutics, 2012, Feb-28, Volume: 423, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, Supercritical Fluid; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Compounding; Humans; Mice; Mice, Inbred BALB C; Nanotechnology; Solvents; Technology, Pharmaceutical; Topoisomerase I Inhibitors; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2012
Neurodevelopmental disorders. New hope for a devastating neurological disorder. Science (New York, N.Y.), 2011, Dec-23, Volume: 334, Issue:6063 Topics: Angelman Syndrome; Animals; Brain; Camptothecin; Drug Evaluation, Preclinical; Gene Expression Regulation; Genetic Therapy; Humans; Irinotecan; Mice; Neurons; Topotecan; Transcriptional Activation; Ubiquitin-Protein Ligases	2011
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. Anti-cancer drugs, 2012, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays	2012
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncology reports, 2012, Volume: 27, Issue:6 Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin	2012
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget, 2012, Volume: 3, Issue:5 Topics: Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; High-Throughput Screening Assays; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Protein Binding; Small Molecule Libraries; Topoisomerase I Inhibitors; Topotecan; Trans-Activators; Transcriptional Activation; Transgenes	2012
Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors. Chemistry & biodiversity, 2012, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; DNA; DNA Cleavage; DNA Topoisomerases, Type I; Humans; Topoisomerase I Inhibitors; Topotecan	2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PloS one, 2012, Volume: 7, Issue:9 Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2012
Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2. G3 (Bethesda, Md.), 2013, Volume: 3, Issue:1 Topics: Animals; BRCA2 Protein; Camptothecin; Cytochrome P-450 Enzyme System; DNA Damage; DNA Primers; DNA Repair; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Genetic Complementation Test; Insect Proteins; Irinotecan; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan	2013
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells. Biochemical pharmacology, 2013, Apr-01, Volume: 85, Issue:7 Topics: Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Interactions; Humans; Phenanthrenes; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostaglandins, Synthetic; Signal Transduction; Topotecan; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2013
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. American journal of clinical oncology, 2015, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome	2015
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2013
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan	2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan	2013
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-15, Volume: 20, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays	2014
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules (Basel, Switzerland), 2014, Feb-17, Volume: 19, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan	2014
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis, 2014, Volume: 17, Issue:3 Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome	2014
Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Marine drugs, 2014, Mar-07, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Porifera; Reactive Oxygen Species; Topotecan	2014
Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum. PloS one, 2014, Volume: 9, Issue:3 Topics: Animals; Antimalarials; Camptothecin; Crystallography, X-Ray; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Inhibitory Concentration 50; Isoflavones; Malaria, Falciparum; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Parasites; Plasmodium berghei; Plasmodium falciparum; Thermodynamics; Topoisomerase Inhibitors; Topotecan	2014
Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester in human breast tumor MCF-7 cells. Molecules (Basel, Switzerland), 2014, Apr-17, Volume: 19, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Calcium; Camptothecin; Cell Cycle; Cell Nucleus; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Female; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Topotecan	2014
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured	2014
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer research, 2014, Dec-01, Volume: 74, Issue:23 Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan	2014
Synthesis of novel 10-hydroxycamptothecin derivatives utilizing topotecan hydrochloride as ortho-quinonemethide precursor. Bioorganic & medicinal chemistry, 2015, Jan-01, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Cycloaddition Reaction; Hep G2 Cells; Humans; KB Cells; Molecular Docking Simulation; Quinones; Topotecan	2015
[DNA topoisomerase I--targeting drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2015
Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ. Biochemical and biophysical research communications, 2015, Aug-07, Volume: 463, Issue:4 Topics: 3T3-L1 Cells; Adipocytes; Animals; Camptothecin; Cell Differentiation; Cell Line, Tumor; Humans; Mice; PPAR gamma; Proteolysis; Topoisomerase I Inhibitors; Topotecan	2015
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PloS one, 2015, Volume: 10, Issue:8 Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan	2015
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Molecular pharmaceutics, 2016, Apr-04, Volume: 13, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan	2016
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science (New York, N.Y.), 2016, May-27, Volume: 352, Issue:6289 Topics: Animals; Azepines; Camptothecin; DNA Topoisomerases, Type I; Ebolavirus; Flavonoids; Gene Expression Regulation; HEK293 Cells; Hemorrhagic Fever, Ebola; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation; Influenza A virus; Interferon-beta; Mice; Mice, Inbred C57BL; Piperidines; Positive Transcriptional Elongation Factor B; RNA Polymerase II; Sendai virus; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Triazoles	2016
Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan. European journal of pharmacology, 2016, Oct-15, Volume: 789 Topics: Actin Cytoskeleton; Antineoplastic Agents; Camptothecin; Cytoskeleton; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; Microtubules; Protein Multimerization; Protein Structure, Quaternary; S Phase Cell Cycle Checkpoints; Topotecan; Tubulin	2016
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner. Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3 Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53	2017
CPT11 prevents virus replication in JCI cells persistently infected with JC polyomavirus. Microbiology and immunology, 2017, Volume: 61, Issue:6 Topics: Antiviral Agents; Camptothecin; Cell Line; Cell Proliferation; DNA Replication; DNA, Viral; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; JC Virus; Leukoencephalopathy, Progressive Multifocal; Naphthoquinones; Real-Time Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan; Viral Proteins; Virus Replication	2017
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-cancer drugs, 2017, Volume: 28, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2017
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors. Journal of immunology research, 2018, Volume: 2018 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53	2018
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs. Chemical communications (Cambridge, England), 2018, Aug-21, Volume: 54, Issue:68 Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan	2018
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer. Anticancer research, 2019, Volume: 39, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan	2019
Hypoxia inducible factor 1 inhibitors for cancer therapy. Minerva chirurgica, 2019, Volume: 74, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Digoxin; Flavonoids; Humans; Hypoxia-Inducible Factor 1; Mustard Compounds; Neoplasms; Oligonucleotides; Phenylpropionates; Polyethylene Glycols; Topotecan	2019
Development of an enzyme‑linked immunosorbent assay for camptothecin. Molecular medicine reports, 2019, Volume: 20, Issue:2 Topics: Animals; Antibodies, Monoclonal; Binding, Competitive; Camptothecin; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Female; Haptens; Hemocyanins; Humans; Immune Sera; Limit of Detection; Mice; Mice, Inbred BALB C; Protein Binding; Topotecan	2019
Engineered liposomes bearing camptothecin analogue for tumour targeting: Journal of liposome research, 2021, Volume: 31, Issue:4 Topics: Animals; Camptothecin; Liposomes; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2021
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan	2020
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:8 Topics: Animals; Autoantibodies; Camptothecin; Cytokines; Disease Models, Animal; Female; Humans; Inflammation Mediators; Kidney; Lupus Nephritis; Proteinuria; Proto-Oncogene Protein c-fli-1; Topoisomerase Inhibitors; Topotecan	2021
Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100. Life sciences, 2022, Dec-15, Volume: 311, Issue:Pt A Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Liver Neoplasms; Mice; Molecular Docking Simulation; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2022
Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study. Molecules (Basel, Switzerland), 2023, Feb-15, Volume: 28, Issue:4 Topics: Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Molecular Docking Simulation; Ribosomal Proteins; Topoisomerase I Inhibitors; Topotecan	2023
Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I. Bioorganic chemistry, 2023, Volume: 139 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; DNA Topoisomerases, Type I; Humans; Liver Neoplasms; Mice; Topoisomerase I Inhibitors; Topotecan	2023